Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia: role of the allogeneic hematopoietic stem cell transplantation
DOI:
https://doi.org/10.46765/2675-374X.2020v1n1p15-18Keywords:
Secondary Myeloid Leukemia, Myelodysplastic Syndrome, Autologous Hematopoietic Stem Cell Transplantation, Relapse, DiagnosisAbstract
Secondary Acute Myeloid Leukemia (s-AML) refers to the development of leukemia after cytotoxic therapy, immunosuppressive therapy, radiation or an antecedent hematological disorder, such as Myelodysplastic Syndrome (MDS). A s-AML corresponds to 10% to 30% of AML cases and is defined by the presence of at least 20% of blast cells, representing a category of disease with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only option with curative potential for patients with s-AML, but recurrence after HSCT emerges as a frequent cause of treatment failure and course with high mortality. We report the case of a patient with s-AML after MDS, who underwent HSCT due to refractoriness to other treatments, recovering the bone marrow with dysplasia, being classified as AREB1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Yhasmine Delles Oliveira Garcia, Juliene Lima Mesquita, Yensy Mariana Zelaya Rosales, Anna Thawanny Gadelha Moura, Beatriz Stela Gomes de Sousa Pitombeira Araujo, João Paulo de Vasconcelos Leitão, Karine Sampaio Nunes Barroso, Lívia Andrade Gurgel, Francisco Dario Rocha Filho, João Vitor Araújo Duarte, Isabella Araújo Duarte, Beatrice Araújo Duarte, Romélia Pinheiro Gonçalves Lemes, Fernando Barroso Duarte

This work is licensed under a Creative Commons Attribution 4.0 International License.
